BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025

Rhea-AI Summary

BioNTech (NASDAQ: BNTX) has scheduled its second quarter 2025 financial results announcement and corporate update for August 4, 2025. The company will host a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) on the same day.

Investors and analysts can access the conference call via telephone by registering through a provided link, which will supply dial-in numbers and a PIN. The presentation slides and webcast will be accessible through the company's website, with a replay available for 30 days after the event.

MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link. 

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

For more information, please visit www.BioNTech.com.

CONTACTS

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

Media Relations
Jasmina Alatovic
Media@biontech.de

FAQ

When will BioNTech (BNTX) report Q2 2025 earnings?

BioNTech will report its Q2 2025 financial results on Monday, August 4, 2025.

What time is BioNTech's Q2 2025 earnings call?

The earnings conference call and webcast will take place at 8:00 a.m. EDT (2:00 p.m. CEST) on August 4, 2025.

How can I access BioNTech's Q2 2025 earnings call?

Investors can access the call by registering via the provided link to receive dial-in numbers and a PIN. The webcast and slides will be available through BioNTech's Investor Relations website.

How long will BioNTech's Q2 2025 earnings call replay be available?

The webcast replay will be archived on BioNTech's website for 30 days following the call.